Clinical Trials Logo

Clinical Trial Summary

Prospective cohort study aimed at simplifying the diagnostic approach to symptomatic patients with the clinical suspicion of deep vein thrombosis (DVT) of the lower extremities. All patients will receive a pre-test clinical probability (PTP) and the determination of D-dimer. Patients with low PTP and negative D-dimer will have the diagnosis ruled out. All other patients will undergo compression ultrasonography (CUS) of the proximal vein system. Patients with negative CUS and either low PTP or negative D-dimer will have the diagnosis ruled out, while those with high PTP and positive D-dimer will undergo extensive ultrasound investigation of the calf vein system. All patients in whom the diagnosis of DVT is ruled out will be followed-up prospectively up to three months for documenting the development of symptomatic thromboembolic events.


Clinical Trial Description

All eligible patients will undergo D-dimer measurement and a formal assessment of pre-test clinical probability (PTP) by means of the Wells score. Patients with unlikely PTP and negative D-dimer will have DVT ruled out and will undergo a 3-month clinical follow-up. If at least one of the two tests is positive, patients will undergo CUS of the proximal vein system by investigating at least the common femoral vein at the groin, the superficial femoral vein at the mid thigh and the popliteal vein(s) in the popliteal fossa. A positive CUS will adjudicate proximal DVT. In the case of negative CUS of the proximal vein system, patients with either negative D-dimer or unlikely PTP will have DVT ruled out, and will undergo a 3-month follow up. Only patients with concomitant likely PTP and positive D-dimer will undergo whole-leg ultrasonography with interrogation of the calf veins. A positive test will adjudicate distal DVT. Patients with negative test will undergo a 3-month clinical follow up.

Follow-up. All patients in whom DVT is ruled out will be monitored for 3 months (either by clinical visit or by telephone contact) after the enrolment in the study. Patients with clinical symptoms of DVT or PE during follow-up will undergo objective diagnostic testing (venous ultrasound for suspected DVT and spiral CT-scan or VQ scan for suspected PE). All source documents will be sent out for an independent adjudication. In case of death, PE diagnosis will be adjudicated by means of autopsy, if available. If autopsy is not available, the adjudication of PE-related death will be done based on clinical documentation.

D-dimer. All quantitative D-dimer tests available at each center will be acceptable for the purpose of this study. D-dimer will be considered negative according to the cut-offs provided by manufacturers.

Sample size. The investigators expect that in every 100 symptomatic outpatients DVT will be excluded without the need for objective testing in approximately 30%, while approximately 20% will have a CUS-detected proximal DVT, approximately 15% will have negative CUS and unlikely PTP in spite of positive D-Dimer (no need for further investigation), approximately 15% will have negative CUS and negative D-Dimer in spite of likely PTP (no need for further investigation, and approximately 20% will have negative CUS and both likely PTP and positive D-Dimer (thus requiring interrogation of the calf vein system).

The investigators hypothesize that the incidence of venous thromboembolic events during follow up in patients labeled as not having DVT will not exceed 1% with the application of the proposed algorithm, and that the upper limit of the 95% confidence intervals around this proportion will not exceed 2%. Accordingly, ap proximately 1100 patients should be enroled. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


NCT number NCT01412242
Study type Interventional
Source University of Padova
Contact
Status Completed
Phase Phase 3
Start date March 2011
Completion date September 2014

See also
  Status Clinical Trial Phase
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT02889562 - Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation Phase 2/Phase 3
Completed NCT01333618 - Introducer Curving Technique for Tilt of Transfemoral Günther Tulip Inferior Vena Cava Filter N/A
Completed NCT00812370 - The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids Phase 1
Completed NCT02552420 - The Clinical Application of Infrared Thermal Imaging Detecting Venous Thromboembolism Phase 2/Phase 3
Completed NCT00178789 - Sonography Outcomes Assessment Program for Lower Extremity Deep Venous Thrombosis Phase 1/Phase 2
Completed NCT03251963 - Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients Phase 2
Completed NCT03286985 - The Prevalence and Incidence of DVT in General ICU
Completed NCT04414332 - Registry of Angiovac Procedures In Detail Outcomes Database-RAPID Registry
Completed NCT02211326 - Genotype-guided Warfarin Individualized Treatment N/A
Completed NCT03296280 - Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
Recruiting NCT03937583 - Screening for Cancer in Patients With Unprovoked VTE Phase 4
Completed NCT00628576 - Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities Phase 3
Completed NCT04979026 - Clinical Investigation of a Novel Approach for the Prevention of Deep Venous Thrombosis After Total Knee Replacement N/A
Active, not recruiting NCT02318472 - Early Mobilization After Achilles Tendon Rupture N/A
Completed NCT01221805 - STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism Phase 4
Recruiting NCT03740633 - Functional Training for the Prevention of Deep Venous Thrombosis Phase 3
Completed NCT03707665 - Deep Venous Thrombosis Screening in the ICU by Nurses
Recruiting NCT05171049 - A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE Phase 3
Terminated NCT01573169 - PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients Phase 3